Photo source: Wikipedia
The Senate Finance Committee recently took the first step in ensuring greater transparency and accountability in our drug supply chain by investigating the business practices of pharmacy benefit managers (PBMs).
Ranking member Sen. Ron Wyden said in his opening statement: “What PBMs do to earn all those profits is a mystery.”
Read more: Grassley has an opportunity for bipartisan success for patients
